ACTIQ (Oral transmucosal fentanyl citrate)
C8278A/302/ON/MN
Phase 3 small_molecule completed
Quick answer
ACTIQ (Oral transmucosal fentanyl citrate) for Breakthrough Pain is a Phase 3 program (small_molecule) at TEVA PHARMACEUTICAL INDUSTRIES LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TEVA PHARMACEUTICAL INDUSTRIES LTD
- Indication
- Breakthrough Pain
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed